Transience

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on: 
Wednesday, May 8, 2024
Hypoxemia, Supplement, Pulmonology, Patient, Adolescence, Inhalation, ATS, Euphoria, Adrenal insufficiency, Cystic fibrosis, Dizziness, AIM, Oxygen saturation (medicine), Doctor of Philosophy, Conference, Research, Bronchopulmonary dysplasia, Radiation-induced lung injury, Heart rate, Ageing, Transience, Headache, RIS, MRI, Magnetic resonance imaging, Hypoesthesia, Government, Asthma, Risk, COVID-19, Orthostatic hypertension, COPD, Medical imaging

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points: 
  • The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
  • The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
  • After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
  • Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.

Notice Administrator Angeion Group Announces Proposed Settlement in Aqueous Film

Retrieved on: 
Wednesday, October 25, 2023
Water, 3M, Hearing, Safe, EST, LA, Court, Lawsuit, Maintenance, Engineering, Judgement, PO, Broad Street, Special master, Drinking water, Public water system, Transience, Release, PFAS, District court, Claim, Tobacco Master Settlement Agreement, Settlement, Collection, Class representative, Vexatious litigation, Completeness, Pharmaceutical industry, Insurance

PHILADELPHIA, Oct. 25, 2023 /PRNewswire/ -- Angeion Group today issues a reminder that a settlement has been reached with Defendant the 3M Company (3M) in a product liability class action lawsuit. Eligible claimants are all Active Public Water Systems in the U.S. that draw or otherwise collect from any Water Source that, on or before June 22, 2023, was tested or otherwise analyzed for PFAS and found to contain any PFAS at any level; and All Active Public Water Systems in the U.S. that, as of June 22, 2023, do not draw or otherwise collect from any Water Source that was tested or otherwise analyzed for PFAS and found to contain any PFAS at any level and (i) are required to test for certain PFAS under U.S. EPA's UCMR-5, or (ii) serve more than 3,300 people, according to U.S. EPA's SDWIS data system.

Key Points: 
  • All other capitalized terms have the same meaning as in the Settlement Agreement, available at www.PFASWaterSettlement.com .
  • It is the intention of the Settlement Agreement that the definition of "Public Water System" be as broad, expansive, and inclusive as possible.
  • In no event shall 3M be required under the Settlement Agreement to pay any amounts above the Settlement Funds.
  • The Final Fairness Hearing may be postponed, adjourned, or continued by Order of the Court without further notice to the Class.

Polarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs

Retrieved on: 
Friday, September 8, 2023
Xenon, Risk, Partnership, Radiation, Inhalation, Transience, AIM, Doctor of Philosophy, Supplement, Clinical trial, Hypoesthesia, Research, Biomarker, VIDA, MRI, Magnetic resonance imaging, Dizziness, Severe cutaneous adverse reactions, Oxygen saturation (medicine), Patient, Acquisition, Physician, Algorithm, Euphoria, Ageing, Hypoxemia, Heart rate, Headache, Adolescence, Medical imaging, Adult

The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.

Key Points: 
  • The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.
  • “Furthermore, this partnership perfectly aligns with our objective of extending the reach of XENOVIEW™ MRI, to provide tools to physicians that treat patients suffering from chronic lung disease.”
    “VIDA and Polarean are natural partners.
  • Since the technology is based on MRI, it does not expose patients to any ionizing radiation and its associated risks.
  • The dose of XENOVIEW, created through the Polarean HPX hyperpolarization system, is administered in a single 10-15 second breath-hold MRI procedure.

Unum provides extra coverage for pregnancy complications, added cancer benefits and life-threatening illnesses

Retrieved on: 
Monday, July 17, 2023
Exercise, Insurance, Radiation, NOT, Transience, Pre-eclampsia, Financial services, Marketing, NICU, Pulmonary embolism, Supplement, Policy, Bone marrow, Cancer, TIA, ME, UIC, Research, UNM, Transient ischemic attack, New York State Department of Financial Services, Investment, Critical illness insurance, HR, Diagnosis, American Cancer Society, Hospice and palliative medicine, Health, Ischemic colitis, Provident Life & Trust Company, NYSE, Life insurance, Health insurance, Dietary supplement, Unum

Unum's critical illness insurance, which provides benefits upon diagnosis of a serious illness or medical event, is adding more financial protection for policyholders and their families.

Key Points: 
  • Unum's critical illness insurance, which provides benefits upon diagnosis of a serious illness or medical event, is adding more financial protection for policyholders and their families.
  • "Providing coverage that includes enhanced protection for critical illnesses is an investment in the well-being and security for employees, said Tom Dupuis, VP of Products.
  • According to the American Cancer Society, there were 1.9 million new cancer cases diagnosed in the U.S. in 2022.
  • Unum has introduced a new cancer benefit that provides ongoing support and coverage.

Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Retrieved on: 
Monday, May 22, 2023
Osteoarthritis, Nobel Prize, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transience, Shionogi, Marketing, Perception, Breakthrough therapy, TRPV1, Temperature, II, Pain, OA, Acquisition, Patient, European, Joint, Nobel Prize in Physiology or Medicine, System, FDA, Breakthrough, RTX, Food, Safety, Knee, Pharmaceutical industry, Medicine, Physiology

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.

Key Points: 
  • Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.
  • Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis.
  • AACHEN, Germany, May 22, 2023 /PRNewswire/ -- Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee.
  • We are hopeful that the Breakthrough Therapy Designation will help us to bring this non-opioid therapy option more quickly to patients."

Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Retrieved on: 
Monday, May 22, 2023
Osteoarthritis, Nobel Prize, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transience, Shionogi, Marketing, Perception, Breakthrough therapy, TRPV1, Temperature, II, Pain, OA, Acquisition, Patient, European, Joint, Nobel Prize in Physiology or Medicine, System, FDA, Breakthrough, RTX, Food, Safety, Knee, Pharmaceutical industry, Medicine, Physiology

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.

Key Points: 
  • Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.
  • Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis.
  • AACHEN, Germany, May 22, 2023 /PRNewswire/ -- Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee.
  • We are hopeful that the Breakthrough Therapy Designation will help us to bring this non-opioid therapy option more quickly to patients."

Kanazawa University research: Experiments reveal chilli-sensitive molecular structure fluctuation changes in TRPV1

Retrieved on: 
Tuesday, May 9, 2023
Nobel Prize, National academy, 2021 Nobel Prize in Physiology or Medicine, PNAS, Transience, Ligand, TRPV1, Howard Hughes Medical Institute, Capsaicin, Temperature, Noetics, Pain, Fudan University, Literature, Protein, Thermodynamics, Nervous system, Science, AFM, Physiology, Kanazawa University, Microscope, Fine chemical

However, the mechanisms behind the function of TRPV1 have not been clear.

Key Points: 
  • However, the mechanisms behind the function of TRPV1 have not been clear.
  • Now Ayumi Sumino at Kanazawa University in Japan and Motoyuki Hattori at the Fudan University in China and their colleagues provide important insights into this mechanism.
  • Once activated, the TRPV1 channel opens, allowing ions to permeate and signalling to the nervous system that a noxious stimulant is present.
  • Antithetic effects of agonists and antagonists on the structural fluctuations of TRPV1 channel, Proceedings of the National Academy of Sciences May 8, 2023.

Kanazawa University research: Experiments reveal chilli-sensitive molecular structure fluctuation changes in TRPV1

Retrieved on: 
Tuesday, May 9, 2023
Nobel Prize, National academy, 2021 Nobel Prize in Physiology or Medicine, PNAS, Transience, Ligand, TRPV1, Howard Hughes Medical Institute, Capsaicin, Temperature, Noetics, Pain, Fudan University, Literature, Protein, Thermodynamics, Nervous system, Science, AFM, Physiology, Kanazawa University, Microscope, Fine chemical

However, the mechanisms behind the function of TRPV1 have not been clear.

Key Points: 
  • However, the mechanisms behind the function of TRPV1 have not been clear.
  • Now Ayumi Sumino at Kanazawa University in Japan and Motoyuki Hattori at the Fudan University in China and their colleagues provide important insights into this mechanism.
  • Once activated, the TRPV1 channel opens, allowing ions to permeate and signalling to the nervous system that a noxious stimulant is present.
  • Antithetic effects of agonists and antagonists on the structural fluctuations of TRPV1 channel, Proceedings of the National Academy of Sciences May 8, 2023.

FILMS FROM NYFA AUSTRALIA ALUM AND STUDENT SELECTED FOR 2023 GOLD COAST FILM FESTIVAL

Retrieved on: 
Thursday, April 20, 2023
Transience, EMERGE, Education, Testament, Choice, Curriculum, Gold Coast Film Festival, Woman, SIPFEST, Home of the Arts, Gold Coast, DIG, Student, Gold, HOTA, Film industry

This year, from 19 - 30 April 2023, Diploma of Screen and Media in Filmmaking alum Alex Free was selected as a finalist for the Gold Coast Film Festival Emerge!

Key Points: 
  • This year, from 19 - 30 April 2023, Diploma of Screen and Media in Filmmaking alum Alex Free was selected as a finalist for the Gold Coast Film Festival Emerge!
  • This film category showcases student short films that compete for best short, screenplay, and cinematography.
  • Hassan’s Choice was her montage film project during her studies at New York Film Academy Australia, now headed to compete in an international competition.
  • The segment of the festival SIPFEST is the premiere Gold Coast short film festival competition.

Award-Winning Photographer Jeremy Cowart Presents AURAS, a First-of-its-Kind Live Performance Art Event Taking Place at Vū Nashville on May 2, 2023

Retrieved on: 
Tuesday, April 18, 2023
Software, Arts, Museums, Entertainment, Professional Services, Blockchain, Fintech, Data Management, Technology, Cryptocurrency, NFT, Web3, Finance, Metadata, Photograph, Transience, Magic, Life, Lab, Cowart, Foot, Multimedia, Photography, Projection, Non-fungible token, Trust, Nature, Engineering, The Lab, Robotics, News, Social media, Book, Kaleidoscope, OpenSea

A pioneering multidisciplinary project that sits at the intersection of photography, performance, and NFT art, AURAS will produce 10,000 unique images in approximately 20 minutes.

Key Points: 
  • A pioneering multidisciplinary project that sits at the intersection of photography, performance, and NFT art, AURAS will produce 10,000 unique images in approximately 20 minutes.
  • The performance will be live streamed on social media.
  • View the full release here: https://www.businesswire.com/news/home/20230418005652/en/
    During the event on May 2, Cowart will create 10,000 completely unique NFTs in approximately 20 minutes.
  • Current holders of Jeremy’s previous NFT Project, Block Queens, will be given the opportunity for a free mint of AURAS.